Phase 3 study of subcutaneous BI 456906 versus placebo in overweight or obese adults with type 2 diabetes mellitus

Phase 3, randomised, double-blind trial of survodutide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by ——/ 勃林格殷格翰(中国)投资有限公司. Primary endpoints: Percent change in body weight from baseline at Week 76 and Proportion of participants achieving at least 5% weight loss at Week 76. Started Feb 2024; status: completed.